How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about teplizumab

    Anticipated marketing authorisation indication

    2.1

    Teplizumab (Tzield, Sanofi) is expected to be indicated to 'delay the onset of stage 3 type 1 diabetes in adult and paediatric patients 8 years of age and older with Stage 2 type 1 diabetes'.

    Dosage in the marketing authorisation

    2.2

    The dosage schedule will be available in the summary of product characteristics for teplizumab.

    Price

    2.3

    The proposed list price of teplizumab is confidential so cannot be reported here.

    2.4

    The company has a commercial arrangement, which would have applied if teplizumab had been recommended.

    Carbon Reduction Plan

    2.5

    Information on the Carbon Reduction Plan for UK carbon emissions for Sanofi will be included here when guidance is published.